文献速递核素与放射性配体治疗肿瘤 PET/CT

胃泌素释放肽受体拮抗剂[177Lu]Lu-RM2首次人体剂量测定:一种治疗转移性去势抵抗性前列腺癌的放射性药物

First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-03

该首次人体剂量测定研究纳入4例无其他获批治疗选择的mCRPC患者,其中2例接受第二周期治疗,平均给予4.5 ± 0.9 GBq的[177Lu]Lu-RM2。治疗耐受良好,无副作用观察到;肿瘤病灶平均吸收剂量为6.20 ± 3.00 Gy/GBq,胰腺为最高吸收剂量器官(1.08 ± 0.44 Gy/GBq)。结论认为[177Lu]Lu-RM2适用于mCRPC的靶向放疗,肿瘤吸收剂量具有治疗相关性,每个周期的给药活度可增加以最大化肿瘤和转移灶的吸收剂量。

要点

  • 肿瘤病灶平均吸收剂量为6.20 ± 3.00 Gy/GBq,具有治疗相关性。
  • 胰腺是吸收剂量最高的关键器官,平均为1.08 ± 0.44 Gy/GBq。
  • 治疗耐受良好,无副作用观察到。

核心结论

  • GRPr拮抗剂[177Lu]Lu-RM2适用于mCRPC的靶向放疗,因其显示高肿瘤摄取和正常器官快速清除。
  • 肿瘤病灶吸收剂量具有治疗相关性,胰腺是吸收剂量最高的关键器官。
  • 结果提示每个周期的给药活度可增加,以最大化肿瘤和转移灶的吸收剂量。

研究设计与样本

  • 35例无进一步获批治疗选择的mCRPC患者接受[68Ga]Ga-RM2-PET/CT检查,其中4例(平均年龄68岁)接受[177Lu]Lu-RM2治疗。
  • 4例中2例还接受了第二周期治疗,平均给药活度为4.5 ± 0.9 GBq。
  • 剂量测定采用平面全身闪烁显像和上、下腹部SPECT/CT于约1、24、48和72小时进行,并采血。
  • 肾脏、胰腺、肝、脾、胆囊壁和肿瘤病灶的吸收剂量基于定量SPECT/CT按RADAR剂量方案导出,器官质量从CT提取。
  • 骨髓吸收剂量基于系列全身图像和采血按EANM指南计算。

主要发现

  • 所有患者对治疗耐受良好,未观察到副作用。
  • 治疗最初1小时内可见肿瘤病灶和胰腺摄取增加。
  • 胰腺平均吸收剂量为1.08 ± 0.44 Gy/GBq,肾脏为0.35 ± 0.14 Gy/GBq,肝为0.05 ± 0.02 Gy/GBq。
  • 胆囊壁平均吸收剂量为0.07 ± 0.02 Gy/GBq,脾为0.10 ± 0.06 Gy/GBq,红骨髓为0.02 ± 0.01 Gy/GBq。
  • 肿瘤病灶平均吸收剂量为6.20 ± 3.00 Gy/GBq。

关键数值与推荐

  • 肿瘤病灶平均吸收剂量6.20 ± 3.00 Gy/GBq。
  • 胰腺平均吸收剂量1.08 ± 0.44 Gy/GBq,为关键器官中最高。
  • 肾脏平均吸收剂量0.35 ± 0.14 Gy/GBq。
  • 红骨髓平均吸收剂量0.02 ± 0.01 Gy/GBq。
  • 平均给药活度4.5 ± 0.9 GBq。

临床怎么用

  • 对于PSMA表达不足或既往[177Lu]Lu-PSMA-617治疗后PSMA积累较低的mCRPC患者,可考虑GRPr靶向的[177Lu]Lu-RM2治疗。
  • 剂量测定显示胰腺为关键器官,临床应用中需关注胰腺吸收剂量。
  • 肿瘤吸收剂量具有治疗相关性,提示可考虑增加每个周期的给药活度以最大化肿瘤剂量。

局限性

  • 研究仅纳入4例接受治疗的患者,样本量小。
  • 原文未报告长期疗效或安全性随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Besides PSMA, prostate cancer cells also express gastrin-releasing peptide receptor (GRPr) which is therefore a promising target for theranostic approaches. The high affinity GRPr antagonist RM2 can be labeled with beta-emitting radiometals for therapeutic purposes. The aim of this study was to calculate absorbed doses for critical organs and tumor lesions for [177Lu]Lu-RM2 therapy administered in a group of metastatic castration-resistant prostate cancer (mCRPC) patients who had insufficient PSMA expression or showed lower PSMA accumulation after previous cycles of [177Lu]Lu-PSMA-617 therapy. METHODS: Thirty-five patients suffering from mCRPC without further treatment options for approved therapies were examined with [68Ga]Ga-RM2-PET/CT. Out of these, 4 patients (mean age 68 years) were treated with [177Lu]Lu-RM2; two of these also received a 2nd therapy cycle. Mean activity was 4.5 ± 0.9 GBq. For dosimetry, patients underwent planar WB-scintigraphy and SPECT/CT imaging of the upper and lower abdomen at approximately 1, 24, 48, and 72 h p.i. along with blood sampling. Absorbed doses for kidneys, pancreas, liver, spleen, gallbladder wall, and tumor lesions were derived based on quantitative SPECT/CT according to RADAR dosimetry scheme; individual organ masses were extracted from CT. Absorbed dose to bone marrow was calculated based on serial whole-body images and blood sampling according to the EANM guideline. RESULTS: Therapy was well tolerated by all patients and no side effects were observed. An increased uptake in tumor lesions and the pancreas was seen within the first 1 h. Mean absorbed organ doses were 1.08 ± 0.44 Gy/GBq in the pancreas, 0.35 ± 0.14 Gy/GBq in the kidneys, 0.05 ± 0.02 Gy/GBq in the liver, 0.07 ± 0.02 Gy/GBq in the gallbladder wall, 0.10 ± 0.06 Gy/GBq in the spleen, and 0.02 ± 0.01 Gy/GBq for the red bone marrow. The mean dose for tumor lesions was 6.20 ± 3.00 Gy/GBq. CONCLUSIONS: Application of GRPr antagonist [177Lu]Lu-RM2 is suitable for targeted radiotherapy of mCRPC as it shows high tumor uptake and rapid clearance from normal organs. Absorbed doses in tumor lesions are therapeutically relevant. The critical organ receiving the highest absorbed dose was the pancreas. Results suggest that the activity administered for each cycle could be increased to maximize the absorbed dose of tumors and metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kurth J, Krause BJ, Schwarzenböck SM, et al. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31482426. doi:10.1007/s00259-019-04504-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。